Introduction
Randomised controlled clinical trials form the most vigorous basis for evaluation of new therapies. Potential participants, doctors and the lay press frequently view participation in such trials with scepticism. This attitude can create a difficult barrier to recruitment. There is good evidence that the conduct of clinical trials confers benefits for the participants regardless of treatment limb allocation. The Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) offers the opportunity of assessing the effects of the clinical trial process in a hypertensive population.
Background
Trials entail protocols with clearly stated therapeutic goals. These goals reflect the ideals of contemporary clinical practice, but in the trial setting they are formalised and discussed in such a way that both doctors and patients agree the objectives. It may be better to be cared for within the constraints of a clinical trial than by any particular expert clinic. The focus of 'evidence-based medicine' and the purpose of clinical governance recognise the importance of managing clinical conditions according to agreed protocols. These initiatives have arisen not simply from the results of clinical trials but also from recognition of the impact of the rigorous process inherent to their conduct.
Review of cancer chemotherapy results has shown that patients managed within trials fare better in terms of symptom control and outcome than those routinely treated. A large Finnish survey of multiple myeloma showed that patients treated in hospitals that participated in trials had a 10% survival Correspondence: Dr Simon Thom, The Peart-Rose Clinic, St Mary's Hospital, London W2 1NY, UK. E-mail s.thomȰic.ac.uk advantage over those that were treated in other hospitals. 1 The consequence of merely being under closer observation in the context of a clinical trial has been shown to have advantageous effect. This has been termed the 'Hawthorne effect' after findings of behavioural changes in an industrial study at the Western Electric Company in Hawthorne. 2 Changes may be evident in all study participants-the researchers and the volunteers, both the observers and the observed. Treatment need not be 'active' for trial participants to accrue benefit. The power of placebo has recently been re-emphasised by a trial of secretin in the treatment of autism. 3 In this doubleblind placebo-controlled study both secretin-treated children and those that received placebo achieved similar reduction in severity of symptoms. 4 
Study objectives
The objectives of this sub-study are:
(1) To compare levels of blood pressure control prior to trial inclusion and after 6 months within protocol in patients who were previously treated. (2) To compare overall cardiovascular risk score prior to trial inclusion and after 6 months within protocol in patients who were previously treated. (3) To compare cardiovascular events in patients included and randomised within the study with events in patients who have been screened but not included.
The sub-study will address the hypothesis that inclusion within ASCOT may result in improvement in blood pressure control and in overall cardiovascular risk score regardless of treatment allocation. Furthermore the sub-study will test the hypothesis that benefits in terms of reduced cardio-
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Methods
The majority of patients recruited to ASCOT in the UK are identified through General Practice records by being on antihypertensive medication. At the St Mary's centre such patients account for approximately 95% of those randomised. Concurrently four patients are screened at the study centre for each patient that is randomised. Frequently the 'screenees' are found to have sufficient levels of blood pressure and cardiovascular risk to meet the inclusion criteria but are unsuitable because of a previous adverse reaction to study treatment or a specific contraindication to one of the study drugs. Records of the 'screenees' are retained on file.
The study cohort recruited at the St Mary's centre will amount to 1000 randomised patients. More than 900 of these patients will have previously been on treatment for hypertension for at least a year prior to screening. Consequently they have had ample opportunity of receiving 'usual clinical care' and attaining treatment targets. At the baseline examination blood pressure and cardiovascular risk status is evaluated in the setting of existing treatment. These data will be compared with blood pressure values and risk scores after 6 months within the trial. All the data required for this substudy are being collected within the routine of the main protocol.
Comparisons will be made between blood pressures, the risk scores and the number of medications at the two stages. At a later stage events occurring in randomised patients will be compared with those amongst non-randomised 'screenees' matched for cardiovascular risk at baseline. The central ASCOT database and morbidity and mortality flagging of 'screenees' through the National Health Service and the Office of National Statistics will be used for this purpose.
Discussion
Whilst there is a general recognition of the need to answer important therapeutic questions through the conduct of randomised controlled trials only a small proportion of patients within any particular disease category are involved in a trial. There are numerous barriers to trial inclusion beyond those of suitability. For the doctor these may include costs (in terms of time and expense), bureaucracy related to case record forms, and the perception of a restriction to clinical judgment. This latter component may arise from an inappropriate conviction of superior knowledge. Patients commonly harbour anxieties about an 'experimental' process and fear that they may be allocated to a disadvantageous treatment. Increasing awareness of the non-specific advantages of clinical trials may encourage patients and doctors to greater levels of participation. The realisation that the organisational style of management typical of trials can be adopted in routine clinical management can only be beneficial. Ultimately the results of clinical trials are more likely to be rapidly incorporated in such an environment.
